Pfizer And Roche Advance On Their Weight Loss Drug Journeys
Pfizer And Roche Advance On Their Weight Loss Drug Journeys
辉瑞和罗氏在减重药研究道路上取得进展
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE:PFE) moved forward with the once-daily version. On Thursday, Pfizer revealed it will begin studies to evaluate the optimal dose of its weight lose pill during the second half of the year. With the new formulation, Pfizer continues its attempt to catch up to Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NYSE:NVO) who are currently dominating the weight loss drug landscape.
此前Pfizer因患者难以耐受其减肥药品的两次日版本而将其打折，现在改为推出一日版本。周四，Pfizer透露将在年后半段开始对其减肥药品的最佳剂量进行研究评估。凭借新配方，Pfizer继续试图追赶Eli Lilly和Novo Nordisk目前在减肥药品市场上占主导地位。
Pfizer Has Struggled To Catch Up To Eli Lilly And Novo Nordisk
Pfizer一直在努力赶超Eli Lilly和Novo Nordisk
What...
E...
登录免费看全文
登录/注册